ReviewBreast cancer research : BCR2002
Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer?
Review in Breast cancer research : BCR, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection.Human genomics · 2013Pooled it
- Dietary fat in breast cancer survival.Annual review of nutrition · 2013Pooled it
- Trp53 Deficiency Increases the Frequency of Hprt Mutant T Lymphocytes Following High-LET Iron Particle Irradiation of Mice.Environmental and molecular mutagenesis · 2026Article
- Prime Editing, CRISPR-Cas9, and NanoCas Genome Editing for Cancer Treatment.Molecular biotechnology · 2026Review
- Biomarkers Related to Interferon-γ Pathway in Myocardial Ischemia-Reperfusion Injury and the Potential Molecular Mechanisms.Cardiovascular toxicology · 2025Article
- Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy.Molecular cancer · 2024Review
- Monitoring Immune Cell Function Through Optical Imaging: a Review Highlighting Transgenic Mouse Models.Molecular imaging and biology · 2022Review
- Transgenic Mouse Models in Cancer Research.Frontiers in oncology · 2018Review
- Heterogeneous nuclear ribonucleoprotein (hnRNP) L promotes DNA damage-induced cell apoptosis by enhancing the translation of p53.Oncotarget · 2017Article
- TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome.Oncotarget · 2015Article
- Genetically engineered mice as experimental tools to dissect the critical events in breast cancer.Advances in cancer research · 2014Review
- SIRT3 and SIRT4 are mitochondrial tumor suppressor proteins that connect mitochondrial metabolism and carcinogenesis.Cancer & metabolism · 2014Review
- OTX1 expression in breast cancer is regulated by p53.Oncogene · 2011Article
- Trp53 regulates Notch 4 signaling through Mdm2.Journal of cell science · 2011Article
- Signal transduction in transgenic mouse models of human breast cancer--implications for human breast cancer.Journal of mammary gland biology and neoplasia · 2008Review
- Estrogen receptor-positive mammary tumorigenesis in TGFalpha transgenic mice progresses with progesterone receptor loss.Oncogene · 2007Article
- Frequent recombination in telomeric DNA may extend the proliferative life of telomerase-negative cells.Nucleic acids research · 2004Article
- Cell cycle genes in a mouse mammary hyperplasia model.Journal of mammary gland biology and neoplasia · 2004Review
- Cell surface beta1,4-galactosyltransferase function in mammary gland morphogenesis: insights from transgenic and knockout mouse models.Journal of mammary gland biology and neoplasia · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The human p53 tumor suppressor gene TP53 is mutated at a high frequency in sporadic breast cancer, and Li-Fraumeni syndrome patients who carry germline mutations in one TP53 allele have a high incidence of breast cancer. In the 10 years since the first knockout of the mouse p53 tumor suppressor gene (designated Trp53) was published, much has been learned about the contribution of p53 to biology and tumor suppression in the breast through the use of p53 transgenic and knockout mice. The original mice deficient in p53 showed no mammary gland phenotype. However, studies using BALB/c-Trp53-deficient mice have demonstrated a delayed involution phenotype and a mammary tumor phenotype. Together with other studies of mutant p53 transgenes and p53 bitransgenics, a greater understanding has been gained of the role of p53 in involution, of the regulation of p53 activity by hormones, of the effect of mouse strain and modifier genes on tumor phenotype, and of the cooperation between p53 and other oncogenic pathways, chemical carcinogens and hormonal stimulation in mammary tumorigenesis. Both p53 transgenic and knockout mice are important in vivo tools for understanding breast cancer, and are yet to be exploited for developing therapeutic strategies in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.